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Introduction
Integrins are / heterodimeric type I membrane receptors that 
mediate divalent cation–dependent interactions with components 
of the extracellular environment (cells and soluble and matrix 
proteins) leading to changes in cell shape, movement, growth, 
differentiation, and survival (Hynes, 2002). Determination of the 
crystal structure of the ectodomain of V3 (∆TM-V3) in 
the absence and presence of a prototypical RGD ligand revealed 
the modular nature of integrins and clarified the basis of its 
divalent cation–mediated interaction with extracellular ligands 
(Xiong et al., 2001, 2002). The 12 extracellular integrin domains 
are assembled into a head segment mounted on top of two leg 
segments. The integrin head comprises a seven-bladed -propeller 
domain from V and a vWFA (A or I-like) domain from 3 and 
contains the RGD-binding site. The V leg is composed of an 
upper Ig-like thigh domain and a lower calf module consisting of 
two large -sandwich domains, Calf-1 and -2. The 3 leg con-
sists of an upper leg segment comprising a plexin-semaphorin- 
integrin (PSI), an Ig-like hybrid, and integrin IE1 (EGF-like 1) 
domain, followed by a lower leg segment made up of three IE do-
mains (IE2–4) and a novel -tail domain (TD). ∆TM-V3 is 
bent in half at two knee-like joints, the - and -genu, the former 
between the thigh and Calf-2 domains and the latter predicted   
between IE1 and -2 (Xiong et al., 2001), such that the head and 
upper leg segments of the heterodimer contact the lower leg seg-
ments of the same molecule.
Binding of the F3 subdomain of the talin head to the cyto-
plasmic tail of the  subunit breaks an / salt bridge (that nor-
mally stabilizes the inactive state; Wegener et al., 2007), triggering 
a conformational wave that travels through the / transmem-
brane (TM) and lower leg domains to switch the conformationally 
sensitive A domain to a high affinity state, which is a process 
W
e determined the crystal structure of 1TM-V3, 
which represents the complete unconstrained 
ectodomain plus short C-terminal transmem-
brane stretches of the V and 3 subunits. 1TM-V3 is 
more compact and less active in solution when compared 
with ∆TM-V3, which lacks the short C-terminal stretches. 
The structure reveals a bent conformation and defines the 
– interface between IE2 (EGF-like 2) and the thigh 
domains. Modifying this interface by site-directed muta-
genesis leads to robust integrin activation. Fluorescent life-
time imaging microscopy of inactive full-length V3 on 
live  cells  yields  a  donor–membrane  acceptor  distance, 
which is consistent with the bent conformation and does 
not change in the activated integrin. These data are the 
first direct demonstration of conformational coupling of the 
integrin leg and head domains, identify the IE2–thigh inter-
face as a critical steric barrier in integrin activation, and 
suggest that inside-out activation in intact cells may in-
volve conformational changes other than the postulated 
switch to a genu-linear state.
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complete  TM  domains  (V3-cTM).  Functional  experiments 
showed that modifying the defined IE2–thigh interface leads to 
constitutive activation. Fluorescent lifetime imaging microscopy 
(FLIM) using ligated Fab fragment of the anti–V propeller mAb 
17E6 (Mitjans et al. 1995) as fluorescence donor and the plasma 
membrane dye FM4-64 FX as acceptor yielded donor–membrane 
acceptor  separation  distances  consistent  with  the  V3-cTM 
structure model, which did not vary between the inactive and 
active states of the full-length integrin in live cells. These data 
demonstrate a conformational link between the lower leg and 
head domains, define the crystal structure of a near native com-
plete ectodomain, identify a critical steric barrier to activation at 
the IE2–thigh interface, and suggest that the genu-linear state is 
not an obligate feature of inside-out activation.
Results
Expression and biophysical characterization 
of 1TM-V3
Published structures of ∆TM-V3 (Xiong et al., 2001) and 
∆TM-IIb3 (Zhu et al., 2008) lacked the last seven extracellu-
lar residues from the  subunit and P691-D692 from the 3 
subunit (Fig. 1 A). We expressed in insect cells an V3 ecto-
domain, 1TM-V3, encoding all of the missing extracellular 
residues in addition to a four-residue TM extension of each sub-
unit. 1TM-V3 was secreted into the culture supernatant of 
virus-infected High-Five insect cells (Fig. 1 B) and was purified 
by affinity chromatography (Fig. 1 C).
The isocratic elution profiles of purified 1TM-V3 and 
∆TM-V3 were compared on molecular sieve chromatography 
columns in neutral buffer containing the physiological divalent   
cations 1 mM Ca
2+ + 1 mM Mg
2+ (Ca
2+/Mg
2+) or 1 mM of the 
activating cation Mn
2. The apparent hydrodynamic radius (Stokes 
called inside-out activation (Hynes, 2002). Direct evidence for 
the conformational coupling of the lower leg and head domains 
is indirect. And how inside-out activation converts the ecto-
domain to the high affinity state is still ill defined. Modeling the 
lower integrin legs of the ectodomain perpendicular to the plasma 
membrane placed the ligand-binding head near the lipid bilayer, 
seemingly blocking access to macromolecular ligands (for re-
view see Arnaout et al., 2005). A switchblade model (Takagi   
et al., 2002) proposed that disruption of the / cytoplasmic–TM 
domain interfaces converts the bent ectodomain to a genu-linear 
conformation, providing ligand access and allowing A to switch 
to high affinity. An alternate model, the deadbolt, proposed that 
lifting the constraints exerted on A by the lower leg TD can 
induce activation without linearity (Xiong et al., 2003). Com-
plete structural information on the remaining / residues in the 
lower leg segments and the conformationally sensitive IE1/IE2 
region are missing or incomplete in current structures of the 
integrin ectodomains (Xiong et al., 2001; Zhu et al., 2008), and 
knowledge of the distance separating the ligand-binding integrin 
head from the plasma membrane in the inactive and active states 
is crucial to elucidate the conformational transitions and energetics 
of affinity switching in integrins.
In this communication, we engineered a new construct, 
1TM-V3, encoding the complete sequence of the V3 
ectodomain plus the first four TM residues of each subunit. 
1TM-V3 was water soluble at neutral pH and was monomeric, 
which allowed characterization of its biophysical and functional 
properties and a determination of its crystal structure. 1TM-V3 
was hydrodynamically more compact and less active than ∆TM-
V3 in solution. Its crystal structure revealed a bent conforma-
tion and defined the complete structure of the ectodomain, including 
that of the IE1/IE2 region and TM extensions, permitting us to 
build a structure model comprising the bent ectodomain plus the 
Figure 1.  Construction, generation, and purification 
of 1TM-V3. (A) Primary sequence of the exofacial 
residues and TM domain (underlined) of human V 
and 3. The crystal structure of ∆TM-V3 (Xiong 
et al., 2001) ends at Q956 in V and G690 in 3 
(closed arrows); ∆TM-IIb3 terminates at the cor-
responding IIb residue A958 and at G690 in 3 
(Zhu et al., 2008). Open arrows point to the C-
terminal ends of 1TM-V3 (I967 and V696). G989 
in the GFF motif is labeled. (B) Western blot after 
fractionation on 4–12% gradient SDS gels of LM609 
mAb immunoprecipitates from insect cell-free super-
natant  under  nonreducing  (NR)  and  reducing  (R) 
conditions. ∆TM and 1TM indicate ∆TM-V3 and 
1TM-V3, respectively. Lanes 1 and 4 show mo-
lecular mass (mm) markers. The 1TM-V and 1TM-
3 subunits migrated with those from ∆TM-V3, 
as expected for the small (<1%) increase in mass   
caused  by  the  additional  C-terminal  sequences.   
(C) Coomassie-stained purified 1TM-V3 after frac-
tionation on 4–12% gradient SDS gels under non-
reducing conditions. Molecular mass markers in lane 
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V3 in its active or RGD-bound states but not in its inactive 
state (Honda et al., 1995; Faccio et al., 2002).
Crystal structure of 1TM-V3
A new native dataset derived from one 1TM-V3 crystal let us 
determine the structure of the 1TM-V3, including the TM ex-
tensions, at 2.9-Å resolution (Fig. 4). The structure was super-
posable on the ∆TM-V3 structure (Xiong et al., 2001, 2004) 
except for those regions newly expressed, the C-terminal exofacial, 
and the TM residues (Fig. 4 A) and now resolved the IE1 and -2 
domains (Fig. 4, B–D). The nearly parallel exofacial extensions 
I955-P959 (in V) and P688-G690 (in 3) remain close through 
A958 and G690 (C–C = 6.2 Å) and then diverge at an extended 
Pro-rich loop structure in V (P959APMPVP963) before the first 
putative  TM residue V964. Structure search of this Pro-rich 
sequence yielded such loops in two contexts (Protein Data Bank 
numbers 2w55 and 2q0s), suggesting that this extended structure is 
not a crystal artifact but also exists in the native integrin. The first 
TM residues V964 (in V) and I963 (in 3) occupy similar posi-
tions in the structure, but the TM extensions do not assume the 
-helical turns found in the nuclear magnetic resonance (NMR) 
structure of the / TM domains (Lau et al., 2009) and do not 
interact as the result of unfavorable crystal contacts.
The three tandem integrin domains IE2–4 are related by 
an approximately twofold screw axis symmetry and form an ex-
tended module (Fig. 4 C). IE1 is roughly antiparallel to IE2, as 
a result of the bend at the -genu (Fig. 4 C). Each IE domain has 
three disulphides (a–c) having the same connectivity aN-aC, bN-bC, 
cN-cC as that found in other EGF domains (Fig. 4 E; Wouters   
et al., 2005). IE1 lacks disulphide a (aN-aC), thus potentially avoid-
ing a clash with the adjacent PSI domain. A characteristic forth 
N-terminal intradomain disulphide d (dN-dC) occupies an analo-
gous site to the Ca coordination site found in the Ca-binding 
subset of EGF domains (Wouters et al., 2005). IE1–4 each contain 
radius [Rs]) of 1TM-V3 was calculated by reference to the 
elution position of standard proteins (Fig. 2). Rs of 1TM-V3 
changed from 55 ± 0.41 Å (mean ± SD; n = 4) in Ca
2+/Mg
2+ to 58 ±   
0.3 Å in Mn
2+. The Rs values for ∆TM-V3 in Ca
2+/Mg
2+  
and Mn
2+ were 57 ± 1.1 Å and 60 ± 1.1 Å, respectively. Thus, 
the mean Rs value for 1TM-V3 in Mn
2+ differed little from 
that of ∆TM-V3 in Ca
2+/Mg
2+. The small amounts of oligo-
mers in the ∆TM-V3 preparations in the presence of Mn
2+ 
were largely absent in 1TM-V3, and the peak width at half 
height, which is a measure of molecular heterogeneity, was nar-
rower for 1TM than for ∆TM. These data suggest that the short 
C-terminal / extensions introduced in 1TM result in a more 
compact and homogenous molecule in solution.
Binding of soluble 1TM-V3 to 
physiological ligands and to the  
activation-sensitive mAb AP5
We performed dose–response curves to quantify the binding 
of increasing concentrations of 1TM-V3 to immobilized 
FN7–10 in Mn
2+ and in Ca
2+/Mg
2+ (Fig. 3, A and B). Half-maximal 
binding was achieved at 0.1 µg/ml and 6.0 µg/ml, respectively 
(n = 2). For soluble TM-V3, half-maximal binding was 
achieved at 0.15 µg/ml and 1.6 µg/ml, respectively. No binding 
took place to uncoated wells or fibronectin (FN)-coated wells in 
the presence of cilengitide (unpublished data). Soluble 1TM-V3 
formed a stable complex with either FN7–10 (Fig. 3 C) or na-
tive full-length FN (Fig. 3 D and Table S1) in solution in Mn
2+-
containing buffer (Fig. 3 D and Table S1). Also consistent with 
the solid phase binding assays, soluble 1TM-V3 did not form 
a stable complex with either FN7–10 or full-length FN in Ca
2+/
Mg
2+ buffer (Fig. 3 D, inset; Table S1; and not depicted). How-
ever, soluble 1TM-V3 formed a stable complex in 2 mM   
of CaCl2 (or Ca
2+/Mg
2+) buffer with the Fab fragment of AP5 
(Fig. 3 E), a ligand-inducible binding site mAb which binds 
Figure  2.  Hydrodynamic  analyses  of  1TM-
V3  and  ∆TM-V3  by  molecular  sieve 
chromatography. A representative experiment 
(one of four) is shown. Purified ∆TM-V3 or 
1TM-V3 in TBS, pH 7.4, containing 1 mM 
MgCl2 + 1 mM CaCl2 or 0.2 mM MnCl2 was 
analyzed. Each integrin was applied onto a 
precalibrated Superdex S-200 GL column, and 
Stokes radii were derived as described previously 
(Adair et al., 2005). Values next to the major   
peaks indicate peak elution volumes (in milli-
liters). A dashed line was added to emphasize 
the peak shifts. mAU, milli–absorbance unit.JCB • VOLUME 186 • NUMBER 4 • 2009   592
three  strands (A–C), with the first two antiparallel strands   
(A and B) forming a major  sheet found in classical EGF domains. 
Strand C is hydrogen bonded to strand D, which is contributed in 
part by the consecutive domain, with strands C and D forming a 
minor  sheet–like conformation. A short strand D caps the IE4 
domain, which is stabilized by the C601-C604 disulphide linker 
that precedes the start of the TD. In IE1–4, strand D has a charac-
teristic  bulge at a conserved E/N residue (E472, E522, N559 and 
E599, respectively) to allow accommodation of disulphide c; its 
cross-strand partner in strand C is an invariant Gly (G468, G518, 
G555, G595, respectively), which is found typically in class II EGF 
domains (Wouters et al., 2005) and some laminin-type epidermal 
growth factor–like domains (Stetefeld et al., 1996).
IE2 has two characteristically long loops, c (between cN and 
cC) and d (between dN and aN; Fig. 4 E), with the latter housing the 
-genu (Fig. 4 B). The -genu is clearly visible in the electron 
density map despite lack of crystal contacts from symmetry- 
related molecules, which is stabilized by hydrogen bonds to the 
major sheet of IE2. The two long loops and strand A of IE2 face 
the bottom of the thigh domain, making mainly electrostatic con-
tacts with its CC and EF loops (Fig. 4 D). The minor strand of 
IE2 faces the N-terminal segment of PSI and forms ionic and van 
der Waals contacts involving mainly T7-R8 of the PSI domain.
Extending the 1TM structure into the / TM fragment, 
which overlaps with structured residues in the NMR structure 
of IIb3 TM domains (Lau et al., 2009), allowed us to build 
a structure model of the inactive ectodomain plus the com-
plete TM domains (Fig. 4, F–H). In this model, the ligand-
binding site is accessible to macromolecular ligands, and the 
extracellular membrane proximal segment is structured. By 
comparison,  in  the  recent  structure  model  of  the  IIb3   
Figure 3.  Binding of 1TM-V3 to physiological ligands and to the   
Fab fragment of the activation-sensitive mAb AP5. (A and B) Receptor- 
binding  assay  to  immobilized  ligand.  Dose–response  curves  showing 
binding increasing concentrations of ∆TM- or 1TM-V3 to wells coated with 
FN7–10 in the presence of 1 mM Mn
2+ (A) or 1 mM Ca
2+ + 1 mM Mg
2+ 
(B). The data shown are from a representative experiment, one of two con-
ducted. Each point was taken at the end of the assay, and the amount of   
integrin present was measured by quantitative ELISA (see Materials and 
methods for details). No binding took place to uncoated wells run in parallel 
(not depicted). (C) Molecular sieve chromatogram showing the stable bind-
ing of 1TM-V3 to FN7–10 in solution containing 0.2 mM MnCl2. Peak elu-
tion volumes for the 1TM-V3–FN complex and FN7–10 are 10.82 ml and   
14.75  ml,  respectively.  (inset)  Coomassie-stained  SDS-PAGE  under  non-
reducing conditions. Lane 1, molecular mass markers (in kilodaltons); lane 2, 
1TM-V3; lane 3, FN7–10; lane 4, blank; lane 5, FN7–10 from the faster 
peak; lane 6, blank; lane 7, 1TM-V3–FN7–10 complex in the slower 
peak. An 1:1 integrin/FN molar ratio was calculated from the scanned 
gel (see Materials and methods), which is in agreement with previous results 
(Adair et al., 2005). (D) Molecular sieve chromatography of 1TM-V3 
with intact plasma FN in the presence of 0.2 mM Mn
2+ or 1 mM Ca
2+ + 1 mM 
Mg
2+. In Mn
2+-containing buffers, 1TM (Kav of 0.229; 11.58 ml) forms a 
complex with intact FN, which elutes at a Kav of 0.66 (9.0 ml). FN alone 
elutes as a discrete peak at a Kav of 0.127 (10.0 ml). In Ca
2+/Mg
2+ buf-
fers, 1TM runs as a more compact molecule, and coelution with FN reveals 
no indication of complex formation (inset). (E) Molecular sieve chromato-
gram showing complex formation of 1TM-V3 with the Fab fragment of 
mAb AP5 in TBS containing 2 mM CaCl2. The dashed line shows the peak 
elution volume of purified 1TM-V3 alone run on the same column and in 
the same buffer. (inset) Coomassie-stained 12% SDS-PAGE under nonreduc-
ing conditions. Lane 1, molecular mass markers (in kilodaltons); lane 2, 
blank; lanes 3 and 5, purified 1TM-V3 and AP5 Fab, respectively, before 
mixing; lane 4, 1TM-V3–AP5 Fab complex from the slower peak. A 1:1 
integrin/AP5 Fab molar ratio was calculated from the scanned gel (see 
Materials and methods). mAU, milli–absorbance unit.
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Functional effects on activity of full-
length V3 after mutation of features 
structurally defined in the 1TM structure
We assessed the effects on cellular V3 caused by modifying 
the newly defined IE2–thigh interface through a -genu dele-
tion  (-genu),  altering  the  TD–hybrid–IE3  interfaces  by 
breaking two salt bridges (R404A + R633A), and changing the 
A–TD–hybrid interfaces by deleting the TD CD loop plus 
ectodomain plus TM domains (Zhu et al., 2009), this region is 
not structurally defined and assumed to be very flexible in the 
inactive integrin model. However, inserting a flexible linker 
into the extracellular membrane proximal Pro-rich sequence 
of the 2 integrin  subunit CD11b leads to a constitutively 
active integrin (Kamata et al., 2005), suggesting that some ri-
gidity in this region is essential to maintain the integrin in its 
inactive conformation.
Figure 4.  New features of 1TM-V3 crystal structure and hypothetical model of V3 plus the complete TM domains (V3-cTM). (A) Density map (in 
blue; contoured at 1.0 ) of the exofacial and TM extensions. The superposed main chains of 1TM-V3 and ∆TM-V3 (only the lower parts of Calf-2 and 
TD shown from each; Xiong et al., 2004) are in light and dark gray, respectively, except for the new exofacial and TM extensions of 1TM-V3, which are 
shown in red, and the last residues in the ∆TM-V3 structure (Q956 and G690), which are shown in green. (B) Density map (in blue; contoured at 1.0 ) 
and main chain tracing of the -genu (in red) in IE2. The orange sphere in this panel and in C represents the metal ion at the -genu. (C) Ribbon diagram 
of the IE1–IE2 region in a similar orientation to that shown in B. Main chain tracings of IE1, IE2, and -genu are in green, blue, and red, respectively.   
(D) Ribbon diagram showing electrostatic interactions at the IE2–thigh interface. Residues (shown in ball and stick representation) forming a salt bridge, main 
chain, or side chain H-bonds are labeled. Thigh and IE2 are labeled in gray and blue, respectively, with the -genu in IE2 shown in red. Oxygen, nitrogen, 
and carbon atoms are in red, blue and green, respectively. Hydrogen bonds and salt bridges (distance cutoff, 3.5 Å) are represented with red dotted 
lines. (E) Structure alignment and Cys pairing of IE domains. The sequence housing the -genu in IE2 is in blue. The secondary structure elements (strands 
are underlined, and a helix is represented by a cylinder) are shown. The atomic coordinates are deposited in the Protein Data Bank (3IJE). (F–H) Structure 
model of V3 ectodomain plus the complete TM domains (V3-cTM). The model is built by releasing the C termini in the 1TM-V3 structure from their 
respective crystal contacts, such that extracellular P691 and P963 initiate the respective 3 and V TM helices, which is consistent with the known propen-
sity of prolines to strongly stabilize -helical conformations (Senes et al., 2004). (F and G) The resulting movements included a 2.9-Å inward movement 
of P691 of 3 (F) and a rotation of V’s Pro-rich loop at Q956, such that P963 initiates the V TM helix (modeled after IIb’s TM NMR structure; G; Lau   
et al., 2009). The structure model was energy minimized with Modeller (Fiser and Sali, 2003), and the V3 TM side chains were optimized and repacked 
using Rosetta (Rohl et al., 2004). The ribbon diagrams in F and G were generated using PyMOL (DeLano Scientific LLC). (H) A ribbon diagram, which was 
generated using Chimera, of the V3-cTM model showing the orientation of the ectodomain relative to the TM domains. The model predicts that the TM 
domains are at an 30° angle relative to the long axis of Calf-2, with ADMIDAS (adjacent to MIDAS) metal ion (green sphere) at an 45-Å distance from 
the plane parallel to the hypothetical membrane drawn at the C of 3s Pro691. The -genu and propeller metal ions are in orange.JCB • VOLUME 186 • NUMBER 4 • 2009   594
Mn
2+-activated WT V3 did not affect binding of fluorescently 
labeled soluble monomeric FN10, either as WT or as a high affin-
ity form (Fig. 6 A). The RGD ligand cilengitide also triggered an 
increase in hydrodynamic radius of the 17E6–1TM-V3 com-
plex (Fig. 6 B), indicating that 17E6 Fab did not freeze either 
membrane-bound  or  soluble  V3  in  an  inactive  state.  The 
plasma membrane was labeled with FM4-64 FX (FM) as accep-
tor. This dye preferentially inserts into the outer leaflet of the 
membrane of live cells in 1–5 min at 4°C, fluoresces brightly, and 
can be rapidly fixed with ice-cold paraformaldehyde, eliminating 
diffusion on the time scale of FLIM measurements. The standard 
equation to calculate FRET efficiency applies to populations of 
fluorophores in such circumstances and is frequently used in bio-
logical systems to report mean donor–acceptor distances.
Alexa Fluor 488 fluorescence lifetime was first measured 
in inactive WT V3–expressing K562 cells stained with Alexa 
Fluor 488–Fab in 1 mM of CaCl2-containing buffer. A lifetime 
of 2,306 ± 52 ps (mean ± SD) was determined in the absence of 
acceptor (Fig. 6, C and D). When the Alexa Fluor 488–Fab- 
labeled K562 cells were further labeled with the FM membrane 
dye, Alexa Fluor 488 lifetime decreased to 2,056 ± 118 ps (P < 
0.0001), corresponding to a FRET efficiency of 10.8% and a 
mean donor–acceptor separation distance (r) of 88 Å. The re-
spective values for the Mn
2+-activated V3 were 2,322 ± 43 ps 
in the absence of acceptor and 2,087 ± 118 ps (P < 0.0001) after 
addition of the FM dye, corresponding to a FRET efficiency of 
10.1% and a mean donor–acceptor separation distance (r) of 89 Å. 
This distance is consistent with the hypothetical structure model 
depicted in Fig. 4 H, which predicts an 90-Å distance from 
the centroid of the integrin-bound 17E6 Fab to the plane of the 
membrane parallel drawn at the C of 3’s P691 residue. Mean 
donor–acceptor separation distances of 78 ± 9 Å (mean ± SD) 
and 83 ± 3 Å were obtained with unliganded V3 and with 
high affinity FN10-bound V3, respectively, each in 1 mM of 
Mn
2+-containing  buffer.  FLIM  measurements  conducted  on 
transiently transfected HEK 293T cells expressing WT, G989FF/
GAA, or -genu V3 in 1 mM of Mn
2+-containing buffer 
an R633A substitution (CD + R633A). The activating G989FF/
GAA mutation (Zhu et al., 2007) served as a positive control. 
None of the mutations impaired expression or heterodimer for-
mation compared with wild type (WT), as judged by reactivity 
with  the  3-specific AP3  mAb  and  the  heterodimer-specific 
LM609 mAb (unpublished data). Mn
2+ increased binding of the 
WT receptor to soluble Alexa Fluor 488–labeled FN9–10 from 
7% in Ca
2+/Mg
2+ buffer to 48% of the AP3-positive cell popula-
tion in Mn
2+. The -genu mutation induced constitutive acti-
vation that was significantly more robust than the G989FF/GAA 
mutant (Fig. 5), with a more modest activation induced by the 
R404A + R633A mutation. The activating effect of the CD + 
R633A mutation was small but significant (P < 0.005; Fig. 5).
FLIM analysis of V3 in live cells
We used FLIM to assess the orientation of the V3 ectodomain 
relative to the plasma membrane in K562 cells stably expressing 
WT V3. For lifetime calculations, FLIM collects only photons 
emitted from the donor fluorophores, thus avoiding the problem 
of mis-excitation of the acceptor and the analogous problem 
of spectral break through bleeding of the donor signal into the 
acceptor spectral window, which are common concerns in spec-
tral fluorescence resonance energy transfer (FRET) applications   
(Chigaev et al., 2001; Kim et al., 2003; Coutinho et al., 2007). 
Importantly, FLIM allows picosecond measurements and is inde-
pendent of concentration of the fluorophores.
As fluorescence energy transfer between a donor–acceptor 
pair described by the Förster equation depends both on the dis-
tance and the relative orientation of donor and acceptor (Jares- 
Erijman and Jovin, 2003; Giepmans et al., 2006), it is critical that 
a structurally defined probe be used as donor. Therefore, we used 
the Fab fragment of mAb 17E6 whose low resolution epitope 
mapping (Mould et al., 2000) corresponds to its crystal structure 
bound to the -propeller of ∆TM-V3, which we have deter-
mined (17E6 binds at the top of the propeller contacting the DA 
loop between blades 2 and 3 and the CD loop in blade 3; unpub-
lished data). Binding of unlabeled 17E6 Fab to the cell surface 
Figure  5.  Effect  of  mutations  based  on  the  TM-V3 
structure on integrin activation. The histogram (mean ± 
SD; n = 3) shows binding of Alexa Fluor 488–FN9–10 to 
WT and mutant surface-expressed V3. The percentage 
of FN9–10-bound cells was expressed as a percentage of 
AP3-bound cells. Binding of WT and each of the mutants 
in Ca
2+/Mg
2+ was then expressed as a percentage of that 
obtained for the Mn
2+-activated WT integrin, with the lat-
ter set at 100.595 CRYSTAL STRUCTURE 1TM-V3 • Xiong et al.
TM domains, (c) functional analyses using the 1TM-V3 crys-
tal structure identified a critical role for the newly defined   
IE2–thigh interface in integrin activation, and (d) FLIM of WT 
V3 in live cells revealed that the apparent distance between 
the integrin head and the plasma membrane changes little in   
inactive, Mn
2+-activated, constitutively active, or FN10-bound 
full-length integrin.
We found that 1TM-V3 is recognized in solution by the 
activation-sensitive mAb AP5 in 2 mM Ca
2+ but did not form a sta-
ble complex in solution with FN7–10 or full-length FN, unless the 
integrin is activated by Mn
2+. Quantitative binding assays showed 
that Kd(app) values of 1TM-V3 and ∆TM-V3 binding to im-
mobilized FN7–10 in Mn
2+ are comparable (0.15 and 0.1 µg/ml). 
However, binding of 1TM-V3 and ∆TM-V3 in Ca
2+/Mg
2+ 
buffer  yielded  Kd(app)  values  that  were  60-fold  and  10-fold 
lower, respectively, than in Mn
2+ (Fig. 3, A and B), reflecting the 
proportion of the active species in each preparation. Thus, 1TM, 
which differs only in the added / lower leg, is less active and   
yielded mean donor–acceptor separation distances of 96 Å, 94 Å, 
and 90 Å, respectively. Thus, the donor–acceptor separation dis-
tances are comparable in the inactive, Mn
2+-activated, constitu-
tively active, or FN10-bound states of the full-length V3 
expressed on the surface of live cells. It is appropriate to men-
tion here that the calculated length of the genu-linear V3 
molecule is >200 Å (Xiong et al., 2001).
Discussion
Our major findings in this study are that (a) the C-terminal ex-
tensions of the V3 ectodomain by the remaining exofacial 
residues and four / TM residues gave a water soluble and con-
formationally stable integrin that is predominantly inactive in 
Ca
2+/Mg
2+ buffer in solution, (b) crystal structure of the near na-
tive 1TM-V3 in Ca
2+ defined the first complete structure of an 
integrin ectodomain plus an / TM fragment and allowed us   
to build a structure model of the ectodomain plus the complete 
Figure 6.  FLIM analysis of V3 in live cells. (A) Histogram (mean ± SEM; n = 2) showing binding of subsaturating Alexa Fluor 488–labeled WT (open 
bars) and high affinity (h; shaded bars) FN10 to full-length WT V3 stably expressed on K562 in the absence () or presence (+) of saturating amounts 
of unlabeled 17E6 Fab in 1 mM Mn
2+ (see Materials and methods). (B) Isocratic molecular sieve elution profiles in Mn
2+-containing TBS buffer. 1TM-V3 
(black) and its complexes with cilengitide (red), 17E6 Fab (blue), and 17E6 Fab complex followed by the addition of cilengitide to 10 µM (green) were 
resolved. The elution profile of 17E6 Fab alone is also shown (violet). Cilengitide runs in the column volume. Cilengitide triggers an increase of the apparent 
Stokes radius of the 1TM-V3–17E6 Fab complex. mAU, milli–absorbance unit. (C) Histogram (mean ± SD) showing lifetimes (in picoseconds) of Alexa 
Fluor 488 fluorescence determined by FLIM in inactive (Ca
2+) and active (Mn
2+) full-length V3. *, P < 0.0001 versus donor only. (D) Representative Alexa 
Fluor 488 fluorescence intensity of the unliganded WT integrin. The pseudocolored FLIM images represent donor fluorescence lifetimes on a pixel by pixel 
basis, where shorter lifetimes are located toward the red area of the spectrum and longer lifetimes toward the blue area. Bar, 8 µm.JCB • VOLUME 186 • NUMBER 4 • 2009   596
on the metal ion coordination in A. In the unliganded ∆TM-
IIb3 structure, the LIMBS residue D
217 points toward LIMBS 
(and not away from it as in 1TM-V3) to avoid a clash with a 
hydrophobic residue (Phe191, which is a Trp in all other  sub-
units; Fig. S1). This orientation provides five coordination sites 
for a LIMBS Ca
2+, with the sixth coordination site completed by 
OE1 of E220, which is thus pulled out of the MIDAS pocket, 
allowing coordination of an Mg
2+ at the MIDAS.
As 1TM-V3 is the fourth integrin crystal structure re-
solved in a bent conformation under conditions that activate li-
gand binding in biochemical and cell biological assays, we once 
again addressed the contentious issue of the conformation of the 
integrin V3 at the cell surface. We positioned a FLIM donor 
on the integrin head and an acceptor in the outer face of the 
plasma membrane. FLIM measurements revealed no significant 
change in mean separation distance of the integrin head relative 
to the plasma membrane outer face in Mn
2+-activated WT V3 
compared with the inactive integrin (Fig. 6, C and D). A previ-
ous FRET study measured the distance between an FITC- 
labeled ligand-mimetic peptide as donor and a plasma membrane 
dye as acceptor (Chigaev et al., 2003). There, the change in 
mean distance of closest approach was 50 Å between resting 
and Mn
2+-activated 41. However, as stated by the authors, the 
membrane dye used, R18, has a tendency to flip-flop between 
the outer and inner leaflets of the plasma membrane, introducing 
uncertainty in the measurements. The FLIM methodology we 
have used minimizes this problem and supports a more recent 
cryoelectron  tomography  study  of  liposome-embedded  and 
Mn
2+-activated IIb3 (Ye et al., 2008). Interestingly, high af-
finity soluble monomeric FN10 bound to the WT V3 in Mn
2+ 
or the constitutive activation of V3 by G989FF/GAA or 
∆-genu mutants also failed to trigger an increase in the mean 
donor–membrane acceptor separation distance compared with 
the inactive WT integrin. The simplest explanation for these 
data is that a switch of the integrin from the inactive to the active 
state or its binding to soluble FN10 in live cells can occur with 
little or no genu extension, which is consistent with a recent 
modeling study (Rocco et al., 2008).
The functional experiments presented in this study identify 
a previously unappreciated but critical role for the IE2–thigh 
interface in stabilizing the inactive state (Fig. 7). This is reflected 
by the robust constitutive activation introduced in the surface-
expressed receptor upon deletion of the -genu, which contrib-
utes to this interface. Our results also show that stability of the 
IE2–thigh interface appears to be conformationally linked to the 
lower leg extensions introduced in 1TM-V3. Other mutations 
in the lower leg domain that interrupt two salt bridges linking the 
TD and IE3 to the top and bottom of the hybrid domain, respec-
tively (Fig. 7), revealed that these make a modest contribution to 
stability of the inactive state: in V3, the steric barrier is mainly 
mediated by the IE3–hybrid contact, whereas the TD–hybrid 
contact appears to predominate in IIb3 (Matsumoto et al., 
2008). Our functional experiments also show that TD contacts 
with both A and hybrid domains contribute to stability of the 
inactive  conformation,  although  this  contribution  is  minor  in 
V3 and absent in IIb3 when the TD–A contact alone   
is removed by deleting the CD loop in TD (Zhu et al., 2007). 
hydrodynamically more compact than ∆T, reflecting a conforma-
tional coupling between the lower leg and head domains that regu-
lates integrin activation. Our present findings are also consistent 
with the integrin existing in equilibrium between two major quater-
nary states, inactive (T state) and active (R state; Perutz, 1989), 
with the T state predominating in soluble 1TM-V3 in Ca
2+/Mg
2+ 
buffer. mAb AP5 binds preferentially in Ca
2+ or Ca
2+/Mg
2+ buffer 
to the minor active species (estimated at 2% and 10% in 1TM- 
and ∆TM-V3 preparations, respectively), driving the quaternary 
equilibrium toward the active quaternary state (s) and stabilizing it 
there (Fig. 3 E). The same shift can be accomplished by FN7–10 or 
by native FN but requires Mn
2+ not Ca
2+, presumably because of 
the higher affinity of Mn
2+ to the metal ion–dependent adhesion 
site (MIDAS) that mediates V3 interaction with ligands. Using 
the measured Kd(app) values as approximations of binding affinities, 
the mean difference in energy between the two major quaternary 
states of 1TM- and ∆TM-V3 is estimated at 2.4 kcal/mol and 
1.4 kcal/mol, respectively. It is expected that this value will be even 
higher for the full-length integrin.
The crystal structure of ∆TM-IIb3 at 2.55-Å resolution 
reported (Zhu et al., 2008) while this work was under review ends 
at the equivalent residues to ∆TM-V3 and thus lacks those lower 
leg residues and TM fragments defined in the current 1TM-V3 
structure and shown to regulate affinity. Superposition of the 
∆TM-IIb3 structure onto that of 1TM-V3 using Match-
maker in the Chimera software suite (Pettersen et al., 2004)   
revealed several interesting differences between these two struc-
tures. First, a significant inward rotation of Calf-1 and -2 at the   
-genu in ∆TM-IIb3 resulting from crystal contacts with sym-
metry-related molecules was associated with translational move-
ments in the IE2–4 domains. Second, the -genu is missing in the 
∆TM-IIb3 structure, where it is presumed disordered (Zhu   
et al., 2008). Yet, significant changes appear in the main chain 
flanking the -genu in ∆TM-IIb3 compared with 1TM-V3, 
suggesting proteolytic cleavage within this site in ∆TM-IIb3 
as another likely explanation. Third, the TD of ∆TM-IIb3 
veers toward IE4 and away from the hybrid/A domains, break-
ing the R633-coordinated salt bridge, which stabilizes the 
inactive state of full-length IIb3 (Matsumoto et al., 2008). 
The engineered disulphide linking TD to Calf-2 in ∆TM-IIb3 
may impose these quaternary changes in the TD environment. 
Fourth, the A domain of unliganded ∆TM-IIb3 contained the 
MIDAS and the stimulatory ligand-associated metal-binding site 
(LIMBS) metal ions (Mg
2+ and Ca
2+, respectively), but no metal 
ions were present in the 1TM-V3 2.9-Å structure formed in 
the presence of Ca
2+ (Fig. S1) or in our published 3.1-Å unliganded 
∆TM-V3 structure (Xiong et al., 2001), even when Mn
2+ was 
diffused into the crystals. Lower resolution (Zhu et al., 2008)   
is an unlikely explanation for this difference, as both metal ions 
are overt in the 3.2-Å structure of the ∆TM-V3–cRGD com-
plex (Xiong et al., 2002). Furthermore, in native A isolated from 
the 3 subunit, LIMBS did not bind Ca
2+ (Pesho et al., 2006), so 
the absence of a LIMBS Ca
2+ in unliganded 3 is independently 
supported. Whether clasping the legs covalently by an artificial 
disulphide permits metal occupancy at LIMBS through allosteric 
mechanisms remains an open question. A likely interpretation is 
that the difference reflects an influence of the associated  subunit 597 CRYSTAL STRUCTURE 1TM-V3 • Xiong et al.
The shape of the quaternary R (active) state of the integrin 
ectodomain remains to be defined structurally. But it includes the 
high affinity state of A and a proposed genu-linear conformation, 
which, it is argued, is required for switching A to the active state 
(Takagi et al., 2002). In the homologous A domain, the high affin-
ity state is characterized by an inward movement of the N-terminal 
1 helix and a two-turn downward movement of the C-terminal   
7 helix, which is permitted by a flexible long linker distally (Lee   
et al., 1995). The former movement was observed in the crystal 
structure of the bent cRGD-bound ∆TM-V3 (Xiong et al., 2002) 
but in the absence of the axial movement of 7 helix, which is 
constrained distally in the bent crystal structure by the hybrid 
domain. The activating effect of releasing constraints on the 
hybrid in the R633 + R404 mutant is consistent with previous work 
performed on integrin ectodomains with modified, truncated, or 
entirely amputated legs (Mould et al., 2003; Xiao et al., 2004), which   
found a correlation between opening the A–hybrid hinge and the 
high affinity state of A. An 70° hinge opening in the legless 
ectodomain structure (Xiao et al., 2004), which is associated with a 
one-turn downward movement of the C-terminal 7 helix, led to the 
conclusion that this feature characterizes the high affinity state of 
A. However, a recent study (Chigaev et al., 2009) found that the 
hybrid domain movement and the high affinity state are regulated 
separately and independently of each other. And an EM study of 
the intact ∆TM-V3 ectodomain complexed with FN7–extra do-
main B–10 detected only a small 11 ± 4° opening of the A–hybrid 
hinge angle (Adair et al., 2005), which is sufficient to break the 
IE2–thigh interface, suggesting that a rather modest hinge opening 
may be all that is needed to switch A to high affinity. Consistently, 
a molecular dynamics study of the legless IIb3 ectodomain de-
tected a spontaneous A–hybrid hinge opening of 20° when a 
single N303-K417 bond linking A to hybrid is broken (Puklin-
Faucher et al., 2006), but over the course of this increase, a lateral 
rather than the axial shift of the A domain C-terminal 7 helix was 
observed. The same study found that subsequent pulling on bound 
FN10 caused the A–hybrid domain hinge to further increase to 70° 
in the legless ectodomain, suggesting that the wider hinge opening 
requires force applied on a ligand-bound integrin. Whether such an 
extreme movement requires preconversion of the ectodomain to a 
genu-linear structure or can occur in a genu-bent conformation re-
quires further study. Our data suggest that overcoming the critical 
IE2–thigh steric barrier through the activating -genu deletion does 
not require a genu-linear conversion. It may also be relevant that 
binding of soluble monomeric high affinity FN10 did not induce 
genu linearity in the full-length V3, suggesting that the high af-
finity state and genu linearity are not conformationally linked events, 
an interpretation which is consistent with experimental observations 
in WT and modified integrins (Takagi et al., 2003; Coutinho et al., 
2007; Gupta et al., 2007). It has been proposed that genu linearity 
requires force applied by the cytoskeleton to the cytoplasmic tails of 
the unliganded integrin (Zhu et al., 2008). However, our FLIM data 
on constitutively active V3 suggest that this remains as bent as 
the inactive molecule. It is possible that the transition to the genu-
linear state requires that force be exerted on both ends of an integrin, 
as when it is bound simultaneously to an immobilized ECM ligand 
and to the cytoskeleton in mechanically stressed tissues (for review 
see Arnaout et al., 2005).
Previous studies have shown that disulphides introduced at the 
TD–A or TD–Calf-2 interfaces blocked integrin activation 
(Takagi et al., 2002; Kamata et al., 2005), suggesting that the 
small barriers at these nodes must also be overcome in the con-
formational switch of the integrin to the active state. Collectively, 
these data suggest that binding of the F3 subdomain of talin to 
the 3 cytoplasmic tail (mimicked by the G989FF/GAA mutant; 
Wegener et al., 2007) unravels the / TM packing, triggering 
movement of the membrane-proximal lower leg domains, reduc-
ing the energy cost of destabilizing the critical IE2–thigh inter-
face (Fig. 7), which then drives the conformational equilibrium 
toward the quaternary R state almost completely (Fig. 5).
Figure 7.  Ribbon diagram showing functionally relevant ionic contacts 
in the 1TM-V3 structure. IE2 makes several electrostatic contacts with 
two conserved loops at the bottom of the thigh domain. These include 
E500 from IE2 making a salt bridge with the conserved CC loop residue 
K503 and an H-bond with the invariant EF loop residue D550 (both 
from the thigh domain) and the -genu residues E476 and D477 making 
H-bonds with the EF residue E547. Two salt bridges (R633–D393 and 
R404–D550) link the top and bottom of the hybrid domain to TD and IE3, 
respectively. The small TD–A interface (S674–V332, in gray) and an 
H-bond between the TD (D606) and Calf-2 (S749; Kamata et al., 2005) 
are also shown.JCB • VOLUME 186 • NUMBER 4 • 2009   598
Coomassie staining. Using ImageJ software (National Institutes of Health), 
the measured intensities of the stained 1TM-V3 and FN7–10 gel bands 
(Fig. 3 C) were 16,514 arbitrary units and 3,468 arbitrary units, respec-
tively, which is a 4.76:1 ratio, yielding a 1:1 stoichiometry, when the 
molecular masses of 1TM-V3 (180.451 kD) and FN7–10 (39.846 kD) 
are considered (a ratio of 4.53:1).
Binding of 1TM-V3 to the activation-sensitive mAb AP5
Binding of soluble 1TM-V3 to the Fab fragment of the ligand-inducible 
binding site mAb AP5 (provided by P.J. Newman, Medical College of   
Wisconsin, Milwaukee, WI; Honda et al., 1995) was performed by mixing 
the integrin with the Fab in a 1:1.4 stoichiometric ratio for 30 min on ice 
in TBS containing 2 mM CaCl2. The complex was detected by molecular 
sieve chromatography in TBS plus 2 mM CaCl2, and the eluted peaks were 
analyzed on 12% SDS-PAGE followed by Coomassie staining. Band inten-
sities for the unreduced stained gels corresponding to 1TM-V3 and AP5 
Fab (Fig. 3 E) were 7,479.5 arbitrary units (for combined V and 3 
bands)  and  2,074.7  arbitrary  units,  respectively  (integrin/Fab  ratio  of 
3.6:1), yielding a 1:1 stoichiometry, with a molecular mass ratio of 3.6:1 
(the calculated molecular mass of Fab is 50 kD).
mAb and soluble ligand binding to cell surface–expressed V3
WT V3–expressing K562 or transiently transfected HEK cells (6 × 10
5 
cells per sample) were stained in suspension with 10 µg/ml LM609 and 
10 µg/ml AP3 mAbs or 20 µg/ml 17E6 Fab in 100 µl TBS containing 
0.5% BSA plus 1 mM CaCl2 + 1 mM MgCl2 or 1 mM MnCl2 for 30 min at 
RT. After washing, cells were incubated with the fluorophore-conjugated 
anti–mouse IgG or the anti-Fab antibody at 0°C for 30 min, washed, fixed, 
and then analyzed by flow cytometry using the CellQuest software (BD). 
FN binding was assessed in parallel by incubating V3-expressing K562 
or batches of transient-transfected HEK 293T with mAb AP3 at 0°C for 45 
min and then with 10 µg/ml of Alexa Fluor 488–labeled FN9–10 or FN10 
and with Cy3-labeled goat anti–mouse IgG1 in TBS buffer containing 1 mM 
CaCl2 + 1 mM MgCl2 or 1 mM MnCl2 at 20°C for 30 min. After washing, 
cells were fixed and analyzed by flow cytometry, and the percentage of 
AP3-positive cells bound to FN was determined. To assess the effect of un-
labeled 17E6 Fab prebound to cellular V3 on subsequent binding of   
Alexa Fluor 488–FN10, K562 cells were first incubated in the absence or 
presence of a saturating amount of Fab (at 30 µg/ml) as in the previous 
section, washed, incubated at 20°C for 30 min with limiting concentrations 
of WT or high affinity Alexa Fluor 488–FN10 (at 10 µg/ml and 2 µg/ml, 
respectively), and then analyzed by FACS, and binding was expressed as 
the percentage of the LM609-positive cells stained in parallel.
Hydrodynamic shift assay for locked integrin
To investigate whether 17E6 Fab binding locked 1TM-V3 in an inactive 
conformation, 17E6 Fab was incubated in TBS containing 0.2 mM Mn
2+ 
(MBB buffer) with 1TM-V3 (1.5:1 Fab/integrin molar ratio) at 20°C for 
1.5 h. Aliquots were taken and chromatographed at this time point, and 
the preformed complex was challenged by adding cilengitide to an end 
concentration of 10 µM and by incubating at 20°C for 1 h and then re-
solved by molecular sieve chromatography in MBB buffer. The unligated 
and 17E6 Fab–ligated ± cilengitide-treated forms of the 1TM-V3 com-
plex were resolved unequivocally as discrete symmetrical peaks on the mo-
lecular sieve column. The excess 17E6 Fab, eluting at Kav 0.52, served as 
an internal standard. Each column run was repeated at least three times, 
and the mean and SDs for the Kav and elution volumes were calculated 
and compared using a Student’s t test.
Crystallography, structure determination, and refinement
1TM-V3 was crystallized at 4°C by vapor diffusion using the hanging-
drop method. The precipitating solution contained 12% PEG 4K, 0.6 M 
NaCl, 5 mM CaCl2, and 0.1 M Na acetate at pH 5.5. Hexagonal crystals 
grew over 4–5 d to dimensions of 0.3 × 0.4 × 0.15 mm
3. A native x-ray 
diffraction dataset from a single cryocooled crystal was collected using 
the ID19 beamline fitted with a charge-coupled device detector at the 
Advanced Photon Source Facility. All data were indexed, integrated, and 
scaled with the HKL2000 program (Otwinowski and Minor, 1997). Data 
collection statistics are presented in Table I. The structure was solved by 
molecular replacement using the structure of the ∆TM-V3 as the search 
model. The model was refined with the crystallography and NMR system 
(CNS; Brünger et al., 1998) and manually adjusted with O (Jones et al., 
1991). After initial simulated annealing, the model was further refined with 
macromolecular refinement by the maximum-likelihood method (REFMAC; 
Winn et al., 2001). The complete structure of IE1 and -2, the linker between 
Materials and methods
Construction, expression, and purification of 1TM-V3
We generated and cloned a new construct encoding human V residues 
F1-I967 and 3 residues G1-V696 (with each ending with the fourth putative 
TM residue, I967 and V696 of V and 3, respectively; Fig. 1 A) into the 
pacUW31vector, and the resulting 1TM-V3 pacUW31 vector was used to 
produce high titer recombinant 1TM-V3 virus, which was used to infect 
High-Five cells (Invitrogen; Mehta et al., 1998). To assess expression of the sol-
uble recombinant integrin, sterile filtered supernatant was immunoprecipitated 
with the V3 heterodimer-specific antibody LM609 (Cheresh and Spiro, 
1987) conjugated to Affigel-10 beads, and after extraction in SDS-PAGE sam-
ple buffer, 200-µl supernatant equivalents were run on 4–12% gradient SDS 
gels under reducing and nonreducing conditions. After Western blotting, the 
membrane was blocked with skim milk–Tween and probed with mixed bio-
tinylated 20H9 and 2A5 antibodies, directed against the 3 and V subunits, 
respectively,  before  detection  with  anti–biotin-HRP  and  ECL  visualization.   
62 ng of purified ∆TM-V3 was run in parallel as a standard. The hetero-
dimer could also be confirmed directly by capture ELISA using 17E6 (anti-V) 
as capture reagent and AP3 (anti-3) as detection reagent. The 1TM-V3 re-
ceptor was purified for biochemistry and crystallography as previously 
described for the ∆TM-V3 recombinant (Mehta et al., 1998) except that the 
mAb 14D9 (Mitjans et al., 1995) was used in affinity chromatography.
Molecular sieve chromatography of purified 1TM-V3
All molecular sieve chromatography analyses were performed as previ-
ously described (Adair et al., 2005) using precalibrated Superdex 200 
(10/300 GL) columns (GE Healthcare) on an Akta fast protein liquid chro-
matography system (GE Healthcare) running Unicorn 5.01 software (GE 
Healthcare) at a flow rate of 0.4 ml min
1 at 20°C. The elution profiles 
were monitored in-line by UV adsorption at 280 nm. TBS buffer (145 mM 
NaCl and 25 mM Tris-HCl, pH 7.4) containing either Ca and Mg (1 mM 
MgCl2 and 1 mM CaCl2) or Mn (0.2 mM MnCl2) was used throughout. 
5–10 µg of purified ∆TM-V3 or 1TM- V3 was fractionated, and the 
Stokes radii were derived by substituting their peak elution volumes (Ve) in 
the fitted standard curve equation (one-phase exponential fit; Prism; Graph-
Pad Software, Inc.). Identity of resolved peaks was formally confirmed by 
SDS-PAGE and by ELISA using mAb LM609.
Plasmids and stable and transient transfections
Plasmids containing cDNAs encoding WT human full-length V and 3 were 
each  subcloned  in  pcDNA3.  -genu  deletion  (-genu;  residues 
E
472DYRPSQ
482), R404A + R633A, and R633A + CD (residues D
672-K
676) 
mutants in 3 and G989FF/GAA mutant in V were made using PCR-based 
mutagenesis with the QuikChange kit (Agilent Technologies), and authenticity 
was confirmed by DNA sequencing. Plasmids encoding WT human FN7–10 
(P1142 to T1509; provided by H.P. Erickson, Duke University Medical Center, 
Durham, NC; Leahy et al., 1996), FN9–10 (G1326 to T1509), FN10 (S1417 
to T1509), or the high affinity and V3-specific form of FN10 (Richards   
et al., 2003) were expressed in bacteria and purified as described previously 
(Aukhil et al., 1993). pcDNA3 plasmids encoding full-length WT V and 3 
were electroporated into K562 cells (American Type Culture Collection; Gupta 
et al., 2007). Stable K562 clones expressing WT V3 were maintained in 
Iscove’s modified Dulbecco’s medium plus 10% heat-inactivated fetal bovine 
serum, 50 IU/ml penicillin and streptomycin, and 0.5–1.0 mg/ml G418. 
V or 3 mutant pcDNA3 plasmids were cotransfected with plasmids encod-
ing the respective WT subunit into HEK 293T cells using Lipofectamine 2000 
reagent (Invitrogen) according to the manufacturer’s protocol.
Binding of 1TM-V3 to immobilized and soluble ligands
Binding of increasing concentrations (0.001–10 µg/ml) of soluble 1TM-
V3 or ∆TM-V3 to immobilized purified FN type III domains 7–10 
(FN7–10; at 3 µg/ml) was performed in the absence or presence of cyclic-
RGD  (cyclo-[Arg-Gly-Asp-d-Phe-(N-Me)Val]-cilengitide)  or  a  control  cyclic 
RAD peptide in 1 mM CaCl2 + 1 mM MgCl2 or 1 mM MnCl2 (in TBS; 0.1% 
BSA for 3 h at 37°C; Kraft et al., 1999). Binding to uncoated wells was 
performed in parallel. The bound integrin was detected using biotinylated 
LM142 mAb (Millipore) at 2 µg/ml and 1:20,000 HRP-labeled anti-biotin 
antibody (Sigma-Aldrich). Binding of 1TM-V3 to soluble FN7–10 was 
also performed in solution (Adair et al., 2005) by mixing 1TM-V3 with 
FN7–10 (in a 1:1.5 stoichiometric ratio) or with native full-length FN (in a 
5:1 stoichiometric ratio) for 1 h at 37°C in 145 mM NaCl and 25 mM Tris-
HCl, pH 7.4, buffer (TBS) containing 0.2 mM MnCl2 or 1 mM CaCl2 and 
1 mM MgCl2. The presence of the 1TM-V3–FN7–10 complex was de-
tected after molecular sieve chromatography, 8% SDS-PAGE analysis, and 599 CRYSTAL STRUCTURE 1TM-V3 • Xiong et al.
NaCl (TBS) containing 1 mM CaCl2, 1 mM CaCl2 and 1 mM MgCl2, or 1 mM 
MnCl2 for 20 min at 37°C. After two washes, some cells were labeled with 
6–12 µM FM4-64 FX (FM) in TBS containing 1 mM CaCl2, 1 mM CaCl2 and 
1 mM MgCl2, or 1 mM MnCl2 for 5 min on ice, washed once, immediately 
fixed with ice-cold 4% paraformaldehyde, washed, and mounted with GVA 
mount (Invitrogen) under a coverslip. The GVA-mounted slides were kept in 
the dark and used the next day for FLIM acquisition (Bacskai et al., 2003). 
In some experiments, adherent K562 expressing WT V3 were pre-
incubated with saturating amounts (10 µg/ml) of unlabeled high affinity 
FN10 followed by the addition of Alexa Fluor 488–Fab and then processed 
as in the previous section.
FLIM measurements were made on a two-photon microscope (Radi-
ance 2000; Bio-Rad Laboratories) with a femtosecond-pulsed Ti:Sapphire 
Laser (Mai Tai; Spectra-Physics) at 800-nm excitation. Photons were detected 
by microchannel plate photomultiplier tube (MCP R3809; Hamamatsu Pho-
tonics) with time-correlated single photon counting (SPC830; Becker & Hickl) 
to measure fluorescent decay profiles. Decay curves were best fit into mono-
exponential curves using SPCImage software (version 2.6.1.2711; Becker & 
Hickl). Lifetimes for multiple cells (n = 9–14) for each experimental condition 
were compared and evaluated for statistically significant differences from 
control cells (labeled only with donor fluorophore) by analysis of variance 
with Fisher’s post-hoc correction. Percent lifetime decrease, or FRET efficiency 
(E), was calculated as the difference between the excited state of the donor 
in absence of acceptor (D) and in presence of acceptor fluorophore (DA) ac-
cording to the equation E = 1  DA/D. The distance between donor (Fab) 
and acceptor fluorophores, r, was calculated using the following equation 
(Duncan et al., 2004): r = R0(D/DA  1)
1/6, where R0 is the Förster radius, 
the distance at which energy transfer is 50%. We assumed random orienta-
tion for the fluorophore (orientation factor, 
2 = 2/3) in the Fab molecule. 
We approximated R0 as 62 Å based on spectral similarities to the published 
Alexa Fluor 488–Alexa Fluor 568 pair (Invitrogen).
Online supplemental material
Fig. S1 shows a ribbon diagram of the MIDAS face in the 1TM-V3 
and TM-IIb3 structures. Table S1 shows the elution profiles after mo-
lecular sieve chromatography of 1TM-V3 or full-length FN alone and 
in complex. Online supplemental material is available at http://www.jcb 
.org/cgi/content/full/jcb.200905085/DC1.
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